
OPKO Health (OPK) Stock Forecast & Price Target
OPKO Health (OPK) Analyst Ratings
Bulls say
OPKO Health has identified an additional $10 million in annualized cost reductions, which enhances its potential for increased operational efficiency and profitability. The company's BioReference Health (BRH) division is approximately $3 million away from achieving profitability at the operating line, excluding non-recurring costs, with full implementation of cost reductions anticipated in the second half of 2025. Additionally, OPKO is expected to achieve adjusted EBITDA positivity on a forward-looking basis, partly supported by a $5.7 million depreciation and amortization expense recorded in the first quarter.
Bears say
OPKO Health Inc. has reported a disappointing earnings per share (EPS) of -$0.10 for the latest quarter, falling short of expectations by five cents, which raises concerns about its financial performance. The revenue contributions from its BARDA and NGENLA segments were underwhelming, with the latter declining significantly compared to the previous year and meeting only half of anticipated expectations. Given these factors, the negative financial trends point to potential challenges within OPKO Health’s operational efficiency and market demand for its products, leading to a cautious outlook on its stock performance.
This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.
OPKO Health (OPK) Analyst Forecast & Price Prediction
Start investing in OPKO Health (OPK)
Order type
Buy in
Order amount
Est. shares
0 shares